ASH 2022 | Depth of molecular response in patients with TP53m MDS & AML treated with magrolimab and azacitidine
David Sallman, MD, Moffitt Cancer Center, Tampa, FL, comments on data from a Phase I trial of magrolimab and azacitidine in patients with TP53-mutant (TP53m) myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). A genetic analysis using whole-exome sequencing (WES) was undertaken to investigate how depth and quality of response correlate with overall survival (OS) and durability of remission. Results revealed a high concordance of molecular clearance in patients with TP53 mutations who achieve complete remission (CR). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Consultancy; Shattuck Labs: Membership on an entity’s Board of Directors or advisory committees; Kite: Membership on an entity’s Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Incyte: Speakers Bureau; Syndax: Membership on an entity’s Board of Directors or advisory committees; Magenta: Consultancy; Intellia: Membership on an entity’s Board of Directors or advisory committees; BMS: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Aprea: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Agios: Membership on an entity’s Board of Directors or advisory committees; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Syntrix Pharmaceuticals: Research Funding; Lixte: Patents & Royalties: LB-100; Nemucore: Membership on an entity’s Board of Directors or advisory committees
